Janssen & Pharma Mar v. EVER Valinject: Trabectedin Patent Dispute Closed in 141 Days
Janssen Products LP and Pharma Mar SA brought a patent infringement action in the Northern District of Illinois against EVER Valinject GmbH and four co-defendants, asserting US7420051B2 covering the cancer drug Yondelis® (trabectedin) 1 mg/vial. The case was filed October 3, 2024 and terminated February 21, 2025 — resolved in just 141 days.
Pharma patent dispute over Yondelis® ends swiftly in N.D. Illinois
On October 3, 2024, Janssen Products LP and Pharma Mar SA filed a patent infringement complaint in the U.S. District Court for the Northern District of Illinois (Case No. 1:24-cv-09441) against EVER Valinject GmbH, Nexus Pharmaceuticals LLC, Medchemexpress LLC, Ruyuan HEC Pharm Co. Ltd., and Shanghai Haoyuan Chemexpress Co. Ltd. The suit asserted US7420051B2 — a patent covering Yondelis® (trabectedin) 1 mg/vial, a marine-derived anticancer compound approved for soft-tissue sarcoma and ovarian cancer.
The case was assigned to Judge Sunil R. Harjani and concluded on February 21, 2025, just 141 days after filing. The public record reflects a basis of termination of ‘Case Terminated’ without further specification of a merits disposition, settlement agreement, or consent judgment. An early docket entry shows plaintiffs sought court-authorised email service on Chinese defendant Ruyuan HEC Pharm, suggesting international service complications may have influenced the pace or manner of resolution.
The 141-day lifespan is notably short for a multi-defendant pharmaceutical patent case, suggesting early resolution — whether through settlement, voluntary dismissal, or procedural termination — rather than contested litigation. The involvement of Chinese manufacturers and a European distributor alongside a US-based distributor points to a supply-chain enforcement strategy. The precise terms of termination and any commercial arrangements between the parties remain unknown from the public record.
Filing to Case Terminated in 141 days
141 days — faster than the median N.D. Illinois patent case lifespan
Case Terminated: what the record reveals — and what it does not
‘Case Terminated’ — a procedural endpoint without merits detail
A ‘Case Terminated’ basis of termination in PACER reflects that the court has closed the docket but does not specify whether the case ended via settlement, voluntary dismissal, default, or other mechanism. It is procedurally distinct from a judgment on the merits. Parties may have agreed to resolve the dispute privately, and no public ruling on infringement or validity of US7420051B2 has been recorded.
No merits ruling on recordJanssen and Pharma Mar: swift close suggests leverage, not defeat
A case closing in 141 days without a contested merits ruling is typically consistent with a negotiated resolution or a defendant’s early capitulation. For Janssen and Pharma Mar, the absence of a public adverse ruling preserves the enforceability of US7420051B2. Whether any licensing terms, injunctive relief, or damages were obtained privately cannot be confirmed from the public record, but the outcome does not suggest a loss for the patent holders.
Patent validity not adjudicatedFive defendants face unresolved IP exposure on trabectedin
With no invalidity ruling entered, the five defendants — including EVER Valinject, Nexus Pharmaceuticals, Medchemexpress, Ruyuan HEC, and Shanghai Haoyuan Chemexpress — did not achieve a public declaration that US7420051B2 is invalid or not infringed. Any private resolution terms are undisclosed. Defendants who manufacture or distribute trabectedin remain exposed to future enforcement action if the asserted patent is still in force.
No invalidity finding enteredSupply-chain enforcement in oncology: a warning to generic distributors
The breadth of defendants — spanning a European injectable distributor, a US pharmaceutical distributor, Chinese chemical manufacturers, and a chemical supplier — suggests a coordinated IP enforcement action targeting the full trabectedin supply chain. This pattern is consistent with originator pharma strategies to suppress generic or research-grade entry ahead of or post-exclusivity. Companies handling trabectedin API or finished dose should treat this case as a signal to conduct FTO analysis against US7420051B2.
Multi-tier supply chain targetedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Janssen Products, LP | Company | Pharmaceutical patent holder and Yondelis® licensor — holder of US7420051B2Search in Eureka ↗ |
| Co-Plaintiff | Pharma Mar, SA | Company | Search in Eureka ↗ |
| Defendant | EVER Valinject GmbH | Company | EVER Valinject GmbH and four co-defendants: generic/chemical manufacturers and distributors of trabectedinSearch in Eureka ↗ |
| Co-Defendant | NEXUS PHARMACEUTICALS, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Medchemexpress LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Ruyuan HEC Pharm Co., Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Shanghai Haoyuan Chemexpress Co., Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alyssa Margaret Caridis | Attorney | Counsel for Janssen Products, LPSearch in Eureka ↗ |
| Plaintiff counsel | Christine Willgoos | Attorney | Counsel for Janssen Products, LPSearch in Eureka ↗ |
| Plaintiff counsel | Daniel D. Williams | Attorney | Counsel for Janssen Products, LPSearch in Eureka ↗ |
| Plaintiff counsel | Irena Royzman | Attorney | Counsel for Janssen Products, LPSearch in Eureka ↗ |
| Plaintiff counsel | Jonathan J. Liu | Attorney | Counsel for Janssen Products, LPSearch in Eureka ↗ |
| Plaintiff counsel | Kaitlyn Rodnick | Attorney | Counsel for Janssen Products, LPSearch in Eureka ↗ |
| Plaintiff counsel | Thomas Alden James | Attorney | Counsel for Janssen Products, LPSearch in Eureka ↗ |
| Plaintiff counsel | Timothy J. Carroll | Attorney | Counsel for Janssen Products, LPSearch in Eureka ↗ |
| Plaintiff law firm | Orrick Herrington & Sutcliffe LLP | Law Firm | Representing Janssen Products, LPSearch in Eureka ↗ |
| Defendant counsel | Imron T. Aly | Attorney | Counsel for EVER Valinject GmbHSearch in Eureka ↗ |
| Defendant counsel | Kevin Michael Nelson | Attorney | Counsel for EVER Valinject GmbHSearch in Eureka ↗ |
| Defendant law firm | ArentFox Schiff LLP | Law Firm | Representing EVER Valinject GmbHSearch in Eureka ↗ |
| Presiding judge | Judge Sunil R. Harjani | Judge | Illinois Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The docket record reflects a motion by plaintiffs seeking court-authorised email service on Chinese defendant Ruyuan HEC Pharm, rather than a final merits verdict. This suggests the case faced international service complications early in proceedings. The basis of termination — ‘Case Terminated’ — is a procedural closure notation and does not constitute a ruling on infringement or validity of US7420051B2. Both parties’ substantive rights remain undetermined from the public record alone.
US7420051B2 — Trabectedin compound and oncology formulation patent
US7420051B2, filed under application number US11/249172, covers trabectedin — a marine-derived antineoplastic compound marketed as Yondelis® in a 1 mg/vial injectable formulation. Trabectedin is a tetrahydroisoquinoline alkaloid originally isolated from the sea squirt Ecteinascidia turbinata and is approved for treatment of unresectable soft-tissue sarcoma and relapsed platinum-sensitive ovarian cancer. The patent is assigned to Pharma Mar SA, with Janssen Products LP holding commercial rights in relevant markets.
US7420051B2 represents a key commercial barrier to generic or research-grade trabectedin entry in the US market. Given the compound’s complex synthesis and narrow therapeutic indication, the patent’s enforceability has direct implications for any manufacturer, distributor, or researcher handling trabectedin API or finished dose. The multi-defendant enforcement action in this case — targeting entities across Europe, the US, and China — underscores Pharma Mar and Janssen’s strategy of aggressive perimeter defence around this asset.
Should you run an FTO analysis against US7420051B2?
Any company involved in the manufacture, import, distribution, or commercial supply of trabectedin — whether as API, finished dose, or reference standard — should treat US7420051B2 as a primary clearance hurdle in US freedom-to-operate analysis. This case demonstrates that the patent holders are actively monitoring and enforcing the patent against entities at multiple tiers of the supply chain, including overseas manufacturers.
PatSnap Eureka’s FTO Search Agent allows IP and R&D teams to map the claim scope of US7420051B2 against product specifications, identify prosecution history estoppel, and surface potential design-around opportunities. Eureka can also identify related family members and any post-grant proceedings that may affect enforceability, giving teams a complete picture before committing to trabectedin-related commercial activities.
Run a freedom-to-operate analysis on US7420051B2 to assess your product’s exposure
Run FTO in Eureka →Similar trabectedin and oncology small-molecule patent cases in US courts
Explore related pharmaceutical patent infringement cases involving oncology small molecules and marine-derived compounds litigated in US federal district courts.
What this case signals for the oncology small-molecule IP landscape
A five-defendant enforcement action resolved in 141 days reveals how originators use coordinated litigation to police trabectedin supply chains.
Wide defendant nets indicate supply-chain IP enforcement is intensifying
Naming manufacturers, distributors, and chemical suppliers simultaneously is a hallmark of originator pharmaceutical enforcement designed to disrupt supply before generic products reach patients. Companies at any stage of the trabectedin API or finished-dose chain should assess their exposure to US7420051B2 before engaging in commercial activity.
Swift closure without a merits ruling leaves the patent fully enforceable
Because no invalidity or non-infringement finding was entered, US7420051B2 exits this litigation intact and fully assertable. Any company operating in the trabectedin space cannot rely on this case as establishing a freedom-to-operate basis — a formal FTO analysis remains essential.
Janssen v EVER — key questions answered
The case was terminated on February 21, 2025, approximately 141 days after filing. The public docket records the basis of termination as ‘Case Terminated’ without specifying a merits ruling, settlement agreement, or judgment. No finding of infringement or invalidity of US7420051B2 was publicly entered.
The asserted patent is US7420051B2, filed under application US11/249172. It covers trabectedin, the active ingredient in Yondelis® (1 mg/vial injectable), a marine-derived anticancer compound approved for soft-tissue sarcoma and relapsed ovarian cancer. Pharma Mar SA is the patent holder; Janssen Products LP is the commercial licensee.
The five defendants are EVER Valinject GmbH (Germany), Nexus Pharmaceuticals LLC (US), Medchemexpress LLC (US), Ruyuan HEC Pharm Co. Ltd. (China), and Shanghai Haoyuan Chemexpress Co. Ltd. (China). The mix of European, US, and Chinese entities suggests the action targeted multiple tiers of the trabectedin supply chain simultaneously.
No. The ‘Case Terminated’ basis of termination does not constitute a finding of invalidity or non-infringement. Because no merits ruling was entered, US7420051B2 remains fully enforceable. Companies operating in the trabectedin space cannot rely on this case termination as establishing freedom to operate — independent FTO analysis is still required.
Early docket entries reflect a motion by Janssen and Pharma Mar for court-authorised email service on Ruyuan HEC Pharm Co. Ltd., a Chinese defendant. Service of US litigation on Chinese entities is complicated by Hague Convention procedures and Chinese regulations limiting formal service. Court-authorised alternative service via email is a recognised mechanism in US federal courts where conventional channels are impracticable or likely to cause unreasonable delay.
PatSnap Eureka searches patents and litigation data to answer instantly.